ArticlePathogens & immunity2018
Fungal Diseases in the 21st Century: The Near and Far Horizons.
Article in Pathogens & immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 101 citations in OpenAlex.
- High throughput screen reveals four compounds with novel antifungal activity, including a metal-responsive candidate with in vivo efficacy against Candida albicans.Scientific reports · 2026Article
- Emergence of Candida (Candidozyma) auris in Minas Gerais, Brazil: Genomic Surveillance to Guide Rapid Public Health Responses.Mycoses · 2026Article
- From the Ground to the Clinic: The Evolution and Adaptation of Fungi.Journal of fungi (Basel, Switzerland) · 2025Review
- Diverse chemotypes of polyketides as promising antimicrobial agents: latest progress.RSC advances · 2025Review
- A Comprehensive Overview ofJournal of fungi (Basel, Switzerland) · 2025Review
- Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives.Infectious disease reports · 2025Review
- Optimization of LCD-Based 3D Printing for the Development of Clotrimazole-Coated Microneedle Systems.Materials (Basel, Switzerland) · 2025Article
- Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Structure-guided optimization of small molecules targeting Yck2 as a strategy to combat Candida albicans.Nature communications · 2025Article
- Structure-guided optimization of small molecules targeting the yeast casein kinase, Yck2, as a therapeutic strategy to combat Candida albicans.Research square · 2025Article
- Rapid Identification of Clinically RelevantJournal of fungi (Basel, Switzerland) · 2025Article
- Climatic and endothermic thermal stress adaptation may be a major driver of emerging and emergent multidrug resistant fungi.Frontiers in microbiology · 2025Review
- Antibiofilm sustainable strategies: pomegranate extract from agri-food waste as a natural antifungal against emergingFrontiers in microbiology · 2025Article
- Broad antibiosis activity ofFrontiers in microbiology · 2025Article
- Admixture in the fungal pathogen Blastomyces.Genetics · 2024Article
- Genotypic diversity, virulence, and molecular genetic tools inMicrobiology and molecular biology reviews : MMBR · 2024Review
- Tuning interdomain conjugation to enablemSystems · 2024Article
- Combining total synthesis and genetic engineering to probe dihydropyran formation in ambruticin biosynthesis.Chemical science · 2024Article
- Patterns recovered in phylogenomic analysis ofMicrobial genomics · 2024Article
- First Report of the Emerging PathogenJournal of fungi (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Fungal diseases became a major medical problem in the second half of the 20th century when advances in modern medicine together with the HIV epidemic resulted in large numbers of individuals with impaired immunity. Fungal diseases are difficult to manage because they tend to be chronic, hard to diagnose, and difficult to eradicate with antifungal drugs. This essay considers the future of medical mycology in the 21st century, extrapolating from current trends. In the near horizon, the prevalence of fungal diseases is likely to increase, as there will be more hosts with impaired immunity and drug resistance will inevitably increase after selection by antifungal drug use. We can expect progress in the development of new drugs, diagnostics, vaccines, and immunotherapies. In the far horizon, humanity may face new fungal diseases in association with climate change. Some current associations between chronic diseases and fungal infections could lead to the establishment of fungi as causative agents, which will greatly enhance their medical importance. All trends suggest that the importance of fungal diseases will increase in the 21st century, and enhanced human preparedness for this scourge will require more research investment in this group of infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.